Last reviewed · How we verify
pantoloc 40 mg
At a glance
| Generic name | pantoloc 40 mg |
|---|---|
| Also known as | pantoloc, a proton pump inhibitor |
| Sponsor | National Science and Technology Council, Taiwan |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease (PHASE4)
- Stress Ulcer Prophylaxis in the Intensive Care Unit (PHASE4)
- Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications (PHASE4)
- Argon Plasma Coagulation vs Hemoclipping for Bleeding Peptic Ulcers (PHASE4)
- Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients (PHASE4)
- Incretin Effect and Use After Clinical Islet Transplantation (PHASE2)
- Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding (PHASE4)
- Argon Plasma Coagulation for Bleeding Peptic Ulcers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pantoloc 40 mg CI brief — competitive landscape report
- pantoloc 40 mg updates RSS · CI watch RSS
- National Science and Technology Council, Taiwan portfolio CI